You are here: Industry Insights > PREVENT-19

News List

Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial prnasia
February 14, 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373...
Novavax seeks EUA from FDA for Covid-19 vaccine pharmaceutical-business-review
February 01, 2022
Novavax has submitted a request seeking emergency use authorisation (EUA) from the US Food and Drug Administration...
Novavax COVID-19 Vax is 90% Effective in Phase 3 Trial contractpharma
June 15, 2021
NVX-CoV2373 demonstrates 100% protection against moderate and severe disease, 90% efficacy overall, and met the primary endpoint.
Novavax commences crossover arms in Covid-19 vaccine trials pharmaceutical-technology
April 06, 2021
Novavax has announced the start of crossover arms in the ongoing phase IIb South African trial and pivotal phase III UK trial of its Covid-19 vaccine candidate NVX-CoV2373.
Novavax announces initiation of PREVENT-19 pivotal Phase 3 efficacy trial of COVID-19 vaccine in the United States and Mexico worldpharmanews
December 29, 2020
Novavax, Inc. announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company's COVID-19 vaccine candidate.